Regeneron Pharmaceuticals

Clinical Research and Development Efforts Booming in Midst of COVID-19 Health Crisis | PR Newswire | 5/20/2020

… the new coronavirus and reduce the impact of COVID-19.” Mentioned in today’s commentary include: NanoViricides, Inc . (NYSE: NNVC ), Co-Diagnostics, Inc. (NASDAQ: CODX ), Vir Biotechnology, Inc. (NASDAQ: VIR ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Regeneron Pharmaceuticals , Inc. (NASDAQ: REGN ). An article in the Washington Post added: “Because the coronavirus responsible for the Covid-19 pandemic is new to humans, doctors had no specific medicines to treat it at the start …

Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio | PR Newswire | 5/14/2020

… all the possible side effects of Libtayo. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Regeneron Pharmaceuticals and Sanofi at 1-877-542-8296. For more information, please see full Prescribing Information , including Medication Guide . About Regeneron Pharmaceuticals , Inc. Regeneron (NASDAQ: REGN ) is a leading biotechnology company that invents life-transforming medicines for people …

Follow Regeneron Pharmaceuticals:    

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration | PR Newswire | 5/11/2020

… follow @Regeneron on Twitter. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals , Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar …

Regeneron Reports First Quarter 2020 Financial and Operating Results | PR Newswire | 5/5/2020

… Investors and Media” page of Regeneron’s website at www.regeneron.com . A replay of the conference call and webcast will be archived on the Company’s website and will be available for at least 30 days. About Regeneron Pharmaceuticals , Inc. Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, Regeneron’s unique ability to repeatedly and consistently …

Stocks making the biggest moves in the premarket: Pfizer, DuPont, Wayfair, Shake Shack & more | CNBC | 5/5/2020

VIDEO 0:50 00:50 Wall Street set for higher open following late Monday rebound Morning Report Take a look at some of the biggest movers in the premarket: Pfizer (PFE) – The drugmaker and partner BioNTech (BTNX) have begun the first U.S. trial of their experimental coronavirus vaccine . If successful, the vaccine could potentially be ready for U.S. distribution by the end of the year. Alaska Air (ALK) – The airline reported a …

VA to participate in clinical trials for blood plasma therapy, remdesivir and sarilumab | NBC News | 5/2/2020

… Alto, California have joined a clinical trial led by the National Institute of Allergy and Infectious Diseases assessing whether drugs like remdesivir are effective against COVID-19. In Atlanta, the VA is working with Regeneron Pharmaceuticals to assess whether sarilumab, a drug normally taken to treat rheumatoid arthritis, may be an effective treatment. Veteran patients interested in participating can contact VA medical centers in these cities. Share this - Jonathan Dienst …

NBA postpones draft lottery and combine | NBC News | 5/1/2020

… Alto, California have joined a clinical trial led by the National Institute of Allergy and Infectious Diseases assessing whether drugs like remdesivir are effective against COVID-19. In Atlanta, the VA is working with Regeneron Pharmaceuticals to assess whether sarilumab, a drug normally taken to treat rheumatoid arthritis, may be an effective treatment. Veteran patients interested in participating can contact VA medical centers in these cities. Share this - 1h ago …

Nasdaq, the envy of markets! Nasdaq composite erases 2020 losses as big earnings drive gains | MSN | 5/1/2020

… up by companies whose online and automated businesses have proved bulwarks amid a stay-at-home scourge, the gauge is up 30% in two months. The all-weather resilience of companies like Amazon.com and Regeneron Pharmaceuticals has made the Nasdaq the envy of markets, at a time the average U.S. stock is down 18% and forecasts for everything from the economy to earnings to the virus’s trajectory remain hopelessly scattered …

Very Critical Press Coverage Extremely Likely to Affect Regeneron Pharmaceuticals (NASDAQ:REGN) Share Price | 4/30/2020

Canaccord Genuity Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $575.00 (americanbankingnews.com) REGN has been the topic of a number of research analyst reports. Cowen increased their price objective on shares of Regeneron Pharmaceuticals from $386.00 to $495.00 and gave the company a “market perform” rating in a research report on Friday, February 28th. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $379.00 to $466.00 …

North Point Portfolio Managers Corp OH Sells 262 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 4/30/2020

North Point Portfolio Managers Corp OH trimmed its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,657 shares of the biopharmaceutical company’s stock after selling 262 shares during the quarter. Regeneron Pharmaceuticals comprises about 4.2% of North Point Portfolio Managers Corp OH’s portfolio, making the stock its 4th …

Scott & Selber Inc. Makes New Investment in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 4/30/2020

Posted by ABMN Staff on Apr 30th, 2020 // No Comments Scott & Selber Inc. bought a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 2,565 shares of the biopharmaceutical company’s stock, valued at approximately $1,252,000. A number of other hedge funds have also bought and sold shares of the business. Sunbelt …

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Short Interest Up 12.9% in April | 4/30/2020

… day moving average price of $399.88. The firm has a market cap of $60.24 billion, a P/E ratio of 27.96, a price-to-earnings-growth ratio of 1.14 and a beta of 0.52. Regeneron Pharmaceuticals has a 52 week low of $271.37 and a 52 week high of $574.32. Get Regeneron Pharmaceuticals alerts: Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, February 6th. The biopharmaceutical …

Scott & Selber Inc. Invests $1.25 Million in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 4/30/2020

Scott & Selber Inc. Invests $1.25 Million in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Posted by Devon Dixon on Apr 29th, 2020 Tweet Scott & Selber Inc. purchased a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 2,565 shares of the biopharmaceutical company’s stock, valued at approximately $1,252,000. Other hedge funds …

Q1 2020 EPS Estimates for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Reduced by Analyst | Daily Political | 4/30/2020

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Stock analysts at Jefferies Financial Group lowered their Q1 2020 EPS estimates for shares of Regeneron Pharmaceuticals in a report issued on Monday, April 27th. Jefferies Financial Group analyst B. Amin now forecasts that the biopharmaceutical company will post earnings per share of $4.89 for the quarter, down from their prior estimate of $5.91. Jefferies Financial Group currently has a “Buy” rating and a $492.00 …

Commerzbank Aktiengesellschaft FI Sells 3,435 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 4/30/2020

Commerzbank Aktiengesellschaft FI reduced its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 35.3% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,287 shares of the biopharmaceutical company’s stock after selling 3,435 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Regeneron Pharmaceuticals were worth $3,070,000 at the end of the most recent reporting period. Other institutional investors …

Re-Opening New York: Cuomo Names Advisory Board | 4/29/2020

… Maria Imperial – CEO, YWCA White Plains & Central Westchester; Sabrina HoSang Jordan - CEO of Rockland County-based Caribbean Food Delights, Inc.; Dr. Belinda S. Miles - President, SUNY Westchester Community College; Leonard Schleifer – CEO, Tarrytown-based Regeneron Pharmaceuticals ; and Kristine M. Young - President, Orange County Community College. Speaking from Upstate University Hospital in Syracuse, Cuomo said rates of COVID-19 hospitalizations, intubations and intensive care treatments continued to trend downward. He said …

Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to Neutral at Citigroup | 4/29/2020

… of $540.00. Citigroup ‘s price target would indicate a potential upside of 8.78% from the stock’s current price. REGN has been the topic of several other reports. Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $410.00 to $409.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 15th. ValuEngine raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in …

COVID-19 diagnosis yields unsatisfactory information in hearing and shows it’s not easy to rise drugs | 4/29/2020

Posted on April 29, 2020 by admin A unsatisfactory set of information from Regeneron Pharmaceuticals Inc. and Sanofi’s mid-stage clinical hearing contrast rheumatoid arthritis drug Kevzara as a COVID-19 diagnosis underscores a normal ups and downs of drug growth that have now been heightened by a tellurian pandemic. Shares of Regeneron -3.45% were down 1% in trade on Tuesday; Sanofi’s batch forsaken 1.7%. Kevzara was initial due as …

resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology | Globe Newswire | 4/29/2020

… manufacturing process to create best-in-class therapies for patients in need.” Adicet completed an $80 million Series B financing in October 2019 and was backed by OrbiMed Advisors, aMoon2 Fund, Novartis Venture Fund, Regeneron Pharmaceuticals , Inc., Johnson & Johnson Innovation – JJDC, Inc. (JJDC), OCI Enterprises, Inc, KB Investment Co., Ltd., Consensus Business Group, SBI JI Innovation Fund, Samsung Venture Investment Corporation, Handok, Inc., DSC Investment, Inc. and Pontifax. In August …

Re-Opening New York: Cuomo Names Advisory Board | Patch | 4/29/2020

… Maria Imperial – CEO, YWCA White Plains & Central Westchester; Sabrina HoSang Jordan - CEO of Rockland County-based Caribbean Food Delights, Inc.; Dr. Belinda S. Miles - President, SUNY Westchester Community College; Leonard Schleifer – CEO, Tarrytown-based Regeneron Pharmaceuticals ; and Kristine M. Young - President, Orange County Community College. Speaking from Upstate University Hospital in Syracuse, Cuomo said rates of COVID-19 hospitalizations, intubations and intensive care treatments continued to trend downward. He said …

FY2021 EPS Estimates for Regeneron Pharmaceuticals Inc Lifted by Jefferies Financial Group (NASDAQ:REGN) | 4/29/2020

Posted by ABMN Staff on Apr 29th, 2020 // No Comments Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Investment analysts at Jefferies Financial Group lifted their FY2021 earnings per share estimates for shares of Regeneron Pharmaceuticals in a research report issued on Monday, April 27th. Jefferies Financial Group analyst B. Amin now forecasts that the biopharmaceutical company will post earnings per share of $29.95 for the year, up from their previous forecast of …

Regeneron Announces Upcoming Investor Conference Presentations | 4/29/2020

News Releases Regeneron Announces Upcoming Investor Conference Presentations TARRYTOWN, N.Y. , April 29, 2020 / PRNewswire / – Regeneron Pharmaceuticals , Inc. (NASDAQ: REGN ) will webcast management participation as follows: Bank of America Securities Virtual Health Care Conference at 8:20 a.m. ET on Tuesday , May 12, 2020 RBC Capital Markets Virtual Global Healthcare Conference at 9:45 a.m. ET on Tuesday , May 19, 2020 Bernstein’s 36 th Annual Strategic Decisions Conference at 10:00 a.m. ET on …

Regeneron Announces Upcoming Investor Conference Presentations in May 2020 | 4/29/2020

TARRYTOWN, N.Y. Regeneron Pharmaceuticals , Inc. (NASDAQ: REGN ) will webcast management participation as follows: Bank of America Securities Virtual Health Care Conference at 8:20 a.m. ET on Tuesday , May 12, 2020 RBC Capital Markets Virtual Global Healthcare Conference at 9:45 a.m. ET on Tuesday , May 19, 2020 Bernstein’s 36 th Annual Strategic Decisions Conference at 10:00 a.m. ET on Wednesday , May 27, 2020 The sessions may be accessed from the “Investors …

resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology | Benzinga | 4/29/2020

… manufacturing process to create best-in-class therapies for patients in need.” Adicet completed an $80 million Series B financing in October 2019 and was backed by OrbiMed Advisors, aMoon2 Fund, Novartis Venture Fund, Regeneron Pharmaceuticals , Inc., Johnson & Johnson Innovation – JJDC, Inc. (JJDC), OCI Enterprises, Inc, KB Investment Co., Ltd., Consensus Business Group, SBI JI Innovation Fund, Samsung Venture Investment Corporation, Handok, Inc., DSC Investment, Inc. and Pontifax. In August …

2 arthritis drugs show different results in Covid-19 trials | 4/29/2020

… another drug Actemra (tocilizumab) showed benefit in treating seriously ill patients in a trial in France.Announcing the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzara, Sanofi and Regeneron Pharmaceuticals Inc. on Monday said that Kevzara had no notable benefit on clinical outcomes when combining the “severe” and “critical” groups, versus placebo.However, there were negative trends for most outcomes in the “severe” group, while …

COVID-19

Clinical Research and Development Efforts Booming in Midst of COVID-19 Health Crisis | PR Newswire | 5/20/2020

… the impact of the disease and prevent further infection. An article from Johns Hopkins pointed out that the treatment for COVID-19 depends on if the case is mild or more severe. For milder cases … Vir Biotechnology, Inc. (NASDAQ: VIR ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ). An article in the Washington Post added: “Because the coronavirus responsible for the Covid-19 pandemic is new to humans …

Department of Health and Human Services

Regeneron Reports First Quarter 2020 Financial and Operating Results | 5/5/2020

… SARS-CoV-2 antibody “cocktail” treatment advancing rapidly; clinical studies planned for June 2020 Praluent restructuring agreements with Sanofi finalized Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced financial results for the first quarter of 2020 … results. The Company announced an expanded agreement with the U.S. Department of Health and Human Services (HHS) to fund certain research and development activities related to COVID-19 treatments, including REGN-COV2 and the U.S …

Food and Drug Administration

TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials | Yahoo News | 4/28/2020

Google Scholar 25. D.I.S.C.O F. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. In: U.S. Food and Drug Administration. 2017. 26. Company B-MS. Prescribing information ipilimumab (Yervoy®). Princeton; 2018. 27. MERCK & CO. I. Prescribing Information Pembrolizumab (Keytruda®). Whitehouse Station; 2019. 28. Squibb B-M. Prescribing Information Nivolumab (Opdivo®). Princeton; 2019. 29. Regeneron Pharmaceuticals I. Prescribing information cemiplimab (Libtayo®). In: LCC S-AUS. NJ; 2019. 30 …

Medical Research

Sanofi: Premature termination of the phase III trial of Libtayo® (cemiplimab) monotherapy in the first line treatment of advanced non-small cell lung cancer due to a highly significant improvement in | Yahoo News | 4/28/2020

… to chemotherapy Sanofi and Regeneron plan regulatory submissions in 2020 Paris and Tarrytown (New York) – April 27, 2020 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announce that the Phase III trial comparing the PD … with serious illnesses. Founded 30 years ago and led by medical researchers, the company’s unique ability to turn scientific research into drugs has resulted in the development of seven drugs, which have been approved by …

Clinical Data

Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients | PR Newswire | 4/27/2020

… higher-dose Kevzara (400 mg) or placebo No new safety findings were observed for Kevzara use in COVID-19 patients Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi today announced the preliminary results from the Phase … other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any …

Pharmacy Benefit Management

Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival | PR Newswire | 4/27/2020

… 27, Libtayo decreased the risk of death by 32.4% compared to chemotherapy Regeneron and Sanofi plan regulatory submissions in 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi today announced the primary endpoint of overall survival … including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted …

Medicaid

Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival | PR Newswire | 4/27/2020

… 27, Libtayo decreased the risk of death by 32.4% compared to chemotherapy Regeneron and Sanofi plan regulatory submissions in 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi today announced the primary endpoint of overall survival … benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be …

PhRMA

Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress - April 7, 2020 - Zacks.com | 4/7/2020

… cases skyrocket to more than 1.34 million globally. According to Jim Mayne, vice president of science and regulatory advocacy at PhRMA, around 50 vaccines are in early development across the biopharma space, and researchers are … States and by Novartis as Jakavi outside the United States. Regeneron Pharmaceuticals ( REGN - Free Report ) too has identified antibodies, which can possibly treat coronavirus. Moreover, Regeneron and partner Sanofi ( SNY - Free Report ) are also evaluating …

Clinical Research

Covid-19 clinical trials expedited as trials in other diseases put on hold, Northwell exec says - MedCity News | 3/22/2020

… they had started enrolling patients in the trials for Gilead Sciences’ Phase III trial program of remdesivir as well as Regeneron Pharmaceuticals and Sanofi’s Phase II/III trial of Kevzara (sarilumab) for treating patients with … deal with it, said Dr. Christina Brennan, vice president of clinical research at Northwell’s Feinstein Institutes for Medical Research, at the conference. “But another thing is, pretty much across the nation, most other clinical trials …

National Institutes of Health

An updated guide to the coronavirus drugs and vaccines in development | STAT | 3/19/2020

… 1273, a vaccine candidate identified just 42 days after the novel coronavirus was sequenced. The company is working with the National Institutes of Health on a healthy-volunteer study that began earlier this month. If … program to make it easier to respond to future pandemics. Regeneron Pharmaceuticals Approach: Treatment Stage: Preclinical Regeneron has grown into a $50 billion business based on its ability to craft human antibodies out of genetically …

NIH

Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More - March 18, 2020 - Zacks.com | 3/18/2020

… against the novel coronavirus (SARS-CoV-2). This phase I study is being conducted by the National Institutes of Health (NIH) under its own Investigational New Drug (IND) application. The phase I study is evaluating … mRNA-1273. Regeneron Up on Identification of Antibodies for Coronavirus : Regeneron Pharmaceuticals ( REGN - Free Report ) announced that it has identified antibodies, which can possibly treat COVID-19. The company is developing a novel multi-antibody …

CDC

Global Pandemic Reiterates the Need for Infectious Disease Therapeutics | PR Newswire | 3/16/2020

… CDC) indicates that more cases are expected to be detected across the United States as testing capacity in the U.S. increases. And while information so far suggests that most COVID-19 illnesses are mild, a report out of China suggests serious illness occurs in 16% of cases. NanoViricides, Inc. (NYSE: NNVC ), Johnson & Johnson (NYSE: JNJ ), Quest Diagnostics, Inc. (NYSE: DGX ), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ), INOVIO Pharmaceuticals, Inc. (NASDAQ: INO …

Medicare

Eighth Annual Lake Nona Impact Forum Convenes Health And Wellbeing Thought Leaders In Orlando, Florida | PRWeb | 2/25/2020

… T.H. Chan School of Public Health Dean of Faculty Michelle Williams, and Leaders of the American Medical Association, Centers for Medicare & Medicaid Services, and U.S. Food and Drug Administration Deepak Chopra speaks during the Lake … Minds Founder Russell Wilson, Fortune President and CEO Alan Murray, Regeneron Pharmaceuticals, Inc. President and CSO George D. Yancopoulos, KPMG Partner and Vice Chairman Laura Newinski, Massachusetts General Hospital Vice-Chair of Neurology Rudolph Tanzi …

Biotech

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2019 - ResearchAndMarkets.com | Benzinga | 12/4/2019

… them from pipeline. Companies Mentioned A. Menarini Industrie Farmaceutiche Riunite Srl AbbVie Inc Actinium Pharmaceuticals Inc ADC Therapeutics SA Aduro BioTech Inc Affimed GmbH Agios Pharmaceuticals Inc AlfaSigma SpA Alissa Pharma Angiocrine Bioscience Inc Anhui … Northlake International LLC OncoTartis Inc Protheragen Inc RAPT Therapeutics Inc Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Rizen (Suzhou) Biosciences Co Ltd Sanofi Seattle Genetics Inc Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd …

Pain Management

Investigational Drugs Reduce Risk of Death from Ebola Virus Disease | 12/4/2019

… Center and the INRB and licensed to Ridgeback Biotherapeutics and Mapp Biopharmaceutical; REGN-EB3, a monoclonal antibody cocktail developed by Regeneron Pharmaceuticals, Inc.; and remdesivir, an antiviral drug developed by Gilead Sciences, Inc. The Biomedical … and blood pressure (with supportive measures as needed), blood transfusions, pain management, and antibiotics and antimalarials as indicated. The final analysis included 673 participants. The trial began in November 2018 with randomized administration of remdesivir …

University of Connecticut

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

Big Pharma

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… it is important to highlight that substantial collaboration activity, related to RNAi, has been reported in the recent past. Several big pharma players have also demonstrated renewed interest in this field of research. Moreover, during … Investment Quark Pharmaceuticals RA Capital Management Radboud University Regen BioPharma Regeneron Pharmaceuticals Regulus Therapeutics Remeditex Ventures ReNeuron RiboBio Rich Yield Capital Santaris Pharma (Acquired by Roche) Roivant Sciences Rolling Boulder Investment Rosetta Genomics Rubicon Genomics …

National Cancer Institute

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… Therapeutics miReven MirImmune Mirimus Moderna Therapeutics Moore Venture Partners MP Healthcare Venture Management MRL Ventures Fund (MRLV) Nant Capital NantVentures National Cancer Institute (NCI) National Center for Advancing Translational Sciences (NCATS), National Institutes of Health … Investment Quark Pharmaceuticals RA Capital Management Radboud University Regen BioPharma Regeneron Pharmaceuticals Regulus Therapeutics Remeditex Ventures ReNeuron RiboBio Rich Yield Capital Santaris Pharma (Acquired by Roche) Roivant Sciences Rolling Boulder Investment Rosetta Genomics Rubicon Genomics …

Genomics

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… Fund Creative Animodel Creative Biogene CureDuchenne Dana-Farber Cancer Institute Dharmacon Dicerna Pharmaceuticals Domain Associates EcoR1 Capital Eli Lilly Eurofins Genomics Eurogentec Exiqon Fidelity Biosciences FOCUS Media Jiangnanchun Foundation F-Prime Capital GeneCopoeia GeneCust GeneDesign … Investment Quark Pharmaceuticals RA Capital Management Radboud University Regen BioPharma Regeneron Pharmaceuticals Regulus Therapeutics Remeditex Ventures ReNeuron RiboBio Rich Yield Capital Santaris Pharma (Acquired by Roche) Roivant Sciences Rolling Boulder Investment Rosetta Genomics Rubicon Genomics

Precision Medicine

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… Management Alexandria Real Estate Equities Alexion Pharmaceuticals Alnylam Pharmaceuticals Altogen Labs Amgen Amgen Ventures AMSBIO Arbutus Biopharma (previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB … Investment Quark Pharmaceuticals RA Capital Management Radboud University Regen BioPharma Regeneron Pharmaceuticals Regulus Therapeutics Remeditex Ventures ReNeuron RiboBio Rich Yield Capital Santaris Pharma (Acquired by Roche) Roivant Sciences Rolling Boulder Investment Rosetta Genomics Rubicon Genomics …

Diagnostic Tests

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… miRNA Biomarkers in Cardiovascular Diseases 15.5.1. Key Indications 15.5.1.1. Myocardial Infarction (MI) 15.5.1.2. Coronary Artery Disease (CAD) 15.6. miRNA Based Diagnostic Tests 16. SERVICE PROVIDERS FOR RNAi THERAPEUTICS 16.1. Chapter Overview 16.2. List of Service … Investment Quark Pharmaceuticals RA Capital Management Radboud University Regen BioPharma Regeneron Pharmaceuticals Regulus Therapeutics Remeditex Ventures ReNeuron RiboBio Rich Yield Capital Santaris Pharma (Acquired by Roche) Roivant Sciences Rolling Boulder Investment Rosetta Genomics Rubicon Genomics …

Clinical Operations

Director, Program Operations Leader (Early Development) - Tarrytown - Tarrytown, NY, , USA #jobs #Tarrytown pls RT | 11/26/2019

Job Detail for Director, Program Operations Leader (Early Development) - Tarrytown Job Location: Regeneron Pharmaceuticals, Tarrytown, NY, , USA Job Detail for Director, Program Operations Leader (Early Development) - Tarrytown Job Location: Regeneron Pharmaceuticals, Tarrytown, NY, , USA Jobs … in Clinical Trial Management (CTM). This individual is responsible for clinical operations activities and decisions including quality, timelines and budgets related to the conduct of clinical research studies in accordance with applicable regulations, ICH/GCP …

Gene Therapy

Novartis to pay US$9.7 bil in latest bet on novel technology | 11/25/2019

Regeneron Pharmaceuticals Inc and Sanofi. Drugmakers are targeting conditions and technologies that can set them apart from rivals, leaving more room for sales growth and allowing them to charge higher prices in an increasingly cost-conscious market. Narasimhan is adding Medicines Co to a list of purchases that includes AveXis, maker of the US$2.1 million gene therapy Zolgensma, and Endocyte, developer of targeted cancer treatments. The 43-year-old …

American Heart Association

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug | 11/21/2019

… 2 clinical trial of rilonacept in a range of pericarditis populations that were included in a poster presentation at the American Heart Association Scientific Sessions on November 16, 2019.” The firm explained that the “FDA … classified as an investigational drug. Kiniksa exclusively licensed rilonacept from Regeneron Pharmaceuticals Inc. for recurrent pericarditis and certain other indications. The company noted that “rilonacept was discovered and developed by Regeneron and is approved by …

Biosimilars

2019-11-15 | 11/15/2019

Biosimilars for AMD part of Biogen agreement Biogen has entered into an agreement with Samsung Bioepsis to secure exclusive rights to commercialize two ophthalmology biosimilars—SB11, referencing Lucentis (ranibizumab, Genentech) and SB15, referencing Eylea (aflibercept, Regeneron Pharmaceuticals)—in major markets around the world, including the U.S., Canada, Europe, Japan, and Australia. Biosimilars have been shown to have similar efficacy and safety as the original improved biosimilar product, but they have …

GSK

Clinical Research and Development Efforts Booming in Midst of COVID-19 Health Crisis | 5/20/2020

… include: NanoViricides, Inc . (NYSE: NNVC ), Co-Diagnostics, Inc. (NASDAQ: CODX ), Vir Biotechnology, Inc. (NASDAQ: VIR ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ). An article in the Washington Post added: “Because the coronavirus … and VIR-7832, in collaboration with GlaxoSmithKline plc (LSE/NYSE: GSK ). “Remarkably, we believe S309 likely covers the entire family of related coronaviruses, which suggests that, even as SARS-CoV-2 continues to evolve, it …

Inovio

Clinical Research and Development Efforts Booming in Midst of COVID-19 Health Crisis | 5/20/2020

Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ). An article in the Washington Post added: “Because the coronavirus responsible for the Covid-19 pandemic is new to humans, doctors had no specific medicines to treat it at the start of the crisis. A scramble to fill that void is beginning to pay off, with the first medication backed by early clinical data authorized to fight the virus. Efforts …

Teva Pharmaceutical

Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio | PR Newswire | 5/14/2020

TARRYTOWN, N.Y. Regeneron will host investor webcast on Monday, June 1 to discuss oncology program strategy and progress Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced the company will share updates from its diverse clinical oncology … or collaboration agreement, including Regeneron’s agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with …

Teva Pharmaceutical

Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio | PR Newswire | 5/14/2020

TARRYTOWN, N.Y. Regeneron will host investor webcast on Monday, June 1 to discuss oncology program strategy and progress Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced the company will share updates from its diverse clinical oncology … or collaboration agreement, including Regeneron’s agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with …

Pfizer

Stocks making the biggest moves in the premarket: Pfizer, DuPont, Wayfair, Shake Shack & more | 5/5/2020

… higher open following late Monday rebound Morning Report Take a look at some of the biggest movers in the premarket: Pfizer (PFE) – The drugmaker and partner BioNTech (BTNX) have begun the first U.S. trial of … will be “challenging” due to the impact of Covid-19. Regeneron Pharmaceuticals (REGN) – Regeneron reported quarterly profit of $6.60 per share compared to a consensus estimate of $6.13 a share. Revenue beat Wall Street forecasts …

Novartis

Diabetic Retinopathy Market by Type, Treatment, End-user and Region - Forecast to 2025 - ResearchAndMarkets.com | Business & Finance | heraldchronicle.com | 5/1/2020

Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc. Key Questions Answered How has the global diabetic retinopathy market performed so far and how will it perform in the coming years? What are the key regional markets? What is the breakup of the market based on the type? What is the breakup of the market based on the treatment type? What is the breakup of the market based on the end …

Allergan

Diabetic Retinopathy Market by Type, Treatment, End-user and Region - Forecast to 2025 - ResearchAndMarkets.com | Business & Finance | heraldchronicle.com | 5/1/2020

Allergan PLC, Ampio Pharmaceuticals, Bayer Healthcare, BCN Peptides, Genentech, Kowa Group, Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc. Key Questions Answered How has the global diabetic retinopathy market performed so far and how will it perform in the coming years? What are the key regional markets? What is the breakup of the market based on the type? What is the breakup of the market based on the treatment type …

Genentech

Diabetic Retinopathy Market by Type, Treatment, End-user and Region - Forecast to 2025 - ResearchAndMarkets.com | Business & Finance | heraldchronicle.com | 5/1/2020

… Genentech, Kowa Group, Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc. Key Questions Answered How has the global diabetic retinopathy market performed so far and how will it perform in the coming years? What are the key regional markets? What is the breakup of the market based on the type? What is the breakup of the market based on the treatment type? What is the breakup of the market based …

Gilead Sciences

COVID-19 treatment yields disappointing data in trial and shows it’s not easy to develop drugs - MarketWatch | 4/28/2020

A disappointing set of data from Regeneron Pharmaceuticals Inc. and Sanofi’s mid-stage clinical trial testing rheumatoid arthritis drug Kevzara as a COVID-19 treatment underscores the traditional ups and downs of drug development that … thesis changing.” The news follows a turbulent two weeks for Gilead Sciences Inc.’s GILD, -1.53% stock, which has both soared and tumbled on media outlets reporting on leaked data from its closely watched clinical …

Vertex Pharmaceuticals

Vertex (VRTX) Hits Fresh High: Is There Still Room to Run? - April 24, 2020 - Zacks.com | 4/24/2020

Have you been paying attention to shares of Vertex Pharmaceuticals ( VRTX - Free Report ) ? Shares have been on the move with the stock up 19.3% over the past month. The stock hit a new 52-week … Gemphire Therapeutics ( NRBO - Free Report ) , Biogen ( BIIB - Free Report ) , and Regeneron Pharmaceuticals ( REGN - Free Report ) , all of which currently have a Zacks Rank of at least 2 and a VGM Score of at least B …

Bristol-Myers Squibb

Drugmakers’ financial fortunes during Covid-19 may hinge on their product mix | 4/23/2020

… and telemedicine could mitigate some market challenges. Post a comment / Apr 23, 2020 at 8:05 AM Shares 0 Buried within Bristol-Myers Squibb’s announcement last month that it had received Food and Drug Administration approval … Gilead Sciences ; those with the most discretionary products were Amgen , Regeneron Pharmaceuticals and GlaxoSmithKline . Still, everything may not neatly fall along these lines of necessary and discretionary. For instance, Eduardo Schur, global practice leader for …

Bristol-Myers

Drugmakers’ financial fortunes during Covid-19 may hinge on their product mix | 4/23/2020

… and telemedicine could mitigate some market challenges. Post a comment / Apr 23, 2020 at 8:05 AM Shares 0 Buried within Bristol-Myers Squibb’s announcement last month that it had received Food and Drug Administration approval … Gilead Sciences ; those with the most discretionary products were Amgen , Regeneron Pharmaceuticals and GlaxoSmithKline . Still, everything may not neatly fall along these lines of necessary and discretionary. For instance, Eduardo Schur, global practice leader for …

GlaxoSmithKline

Drugmakers’ financial fortunes during Covid-19 may hinge on their product mix | 4/23/2020

Regeneron Pharmaceuticals and GlaxoSmithKline . Still, everything may not neatly fall along these lines of necessary and discretionary. For instance, Eduardo Schur, global practice leader for life sciences at management consulting firm Guidehouse, points to the dermatology sector, a discretionary segment of the broader life science market. Citing prescription data from IQVIA, Schur pointed out that dermatology had actually seen year-over-year growth, even for acne drugs. It’s possible that …

Celgene

Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer Paris Stock Exchange:ALCLS | 4/13/2020

… new role, she will oversee clinical research and development for Cellectis’ UCART clinical trial programs. Dr. Brownstein joins Cellectis from Celgene, with a strong track record in hematology and myeloid diseases. She is assuming her … Dr. Brownstein served as Executive Director, Clinical Sciences Oncology at Regeneron Pharmaceuticals where she led teams investigating multiple early development programs and assets, including T-cell engaging bispecific antibodies. Dr. Brownstein started her industry career …

Incyte

Four Massachusetts companies among a group highlighted by Goldman Sachs for fighting virus | Boston Globe | 4/10/2020

Regeneron Pharmaceuticals Inc., which are expected to report clinical results from experimental COVID-19 treatments this month. Moderna and Johnson & Johnson have the most promising vaccines, analysts said. The other companies are Abbott Laboratories, Adaptive Biotechnologies Corp., Becton Dickinson and Co., BioNTech SE, CSL Ltd., Danaher Corp., Fujifilm Holdings Corp., Grifols SA, Incyte Corp., Laboratory Corp. of America, Novartis AG, Pfizer Inc., Quest Diagnostics Inc., Roche Holding AG, Sanofi, Takeda …

Grifols

Four Massachusetts companies among a group highlighted by Goldman Sachs for fighting virus | Boston Globe | 4/10/2020

Regeneron Pharmaceuticals Inc., which are expected to report clinical results from experimental COVID-19 treatments this month. Moderna and Johnson & Johnson have the most promising vaccines, analysts said. The other companies are Abbott Laboratories, Adaptive Biotechnologies Corp., Becton Dickinson and Co., BioNTech SE, CSL Ltd., Danaher Corp., Fujifilm Holdings Corp., Grifols SA, Incyte Corp., Laboratory Corp. of America, Novartis AG, Pfizer Inc., Quest Diagnostics Inc., Roche Holding AG, Sanofi, Takeda …

Adaptive Biotechnologies

Four Massachusetts companies among a group highlighted by Goldman Sachs for fighting virus | 4/10/2020

Regeneron Pharmaceuticals Inc., which are expected to report clinical results from experimental COVID-19 treatments this month. Moderna and Johnson & Johnson have the most promising vaccines, analysts said. The other companies are Abbott Laboratories, Adaptive Biotechnologies Corp., Becton Dickinson and Co., BioNTech SE, CSL Ltd., Danaher Corp., Fujifilm Holdings Corp., Grifols SA, Incyte Corp., Laboratory Corp. of America, Novartis AG, Pfizer Inc., Quest Diagnostics Inc., Roche Holding AG, Sanofi, Takeda …

Merck

Roche Tops the Pharmaceutical Innovation Index for the First Time; AstraZeneca Ranks 1st for Its Pipeline | PR Newswire | 4/8/2020

Merck & Co 8 -3 Shionogi & Co 9 New Johnson & Johnson 10 +1 Regeneron Pharmaceuticals 10 +7 Pharmaceutical Invention Index 2020 Companies 2020 Pharmaceutical Invention Index Change from 2019 AstraZeneca 1 0 Bristol-Myers Squibb 2 +4 Eli Lilly 3 0 Novartis 4 0 Gilead Sciences 5 +6 Regeneron Pharmaceuticals 6 +1 AbbVie 7 -2 Merck & Co 7 +8 Vertex Pharmaceuticals 9 -4 Roche 10 +2 Commenting on the index, IDEA …

AbbVie

Roche Tops the Pharmaceutical Innovation Index for the First Time; AstraZeneca Ranks 1st for Its Pipeline | PR Newswire | 4/8/2020

AbbVie 2 0 Novartis 3 +6 Vertex Pharmaceuticals 3 New Eli Lilly 5 -2 AstraZeneca 6 +6 Alexion Pharmaceuticals 7 New Merck & Co 8 -3 Shionogi & Co 9 New Johnson & Johnson 10 +1 Regeneron Pharmaceuticals 10 +7 Pharmaceutical Invention Index 2020 Companies 2020 Pharmaceutical Invention Index Change from 2019 AstraZeneca 1 0 Bristol-Myers Squibb 2 +4 Eli Lilly 3 0 Novartis 4 0 Gilead Sciences 5 +6 Regeneron Pharmaceuticals

Merck & Co

Roche Tops the Pharmaceutical Innovation Index for the First Time; AstraZeneca Ranks 1st for Its Pipeline | PR Newswire | 4/8/2020

Merck & Co 8 -3 Shionogi & Co 9 New Johnson & Johnson 10 +1 Regeneron Pharmaceuticals 10 +7 Pharmaceutical Invention Index 2020 Companies 2020 Pharmaceutical Invention Index Change from 2019 AstraZeneca 1 0 Bristol-Myers Squibb 2 +4 Eli Lilly 3 0 Novartis 4 0 Gilead Sciences 5 +6 Regeneron Pharmaceuticals 6 +1 AbbVie 7 -2 Merck & Co 7 +8 Vertex Pharmaceuticals 9 -4 Roche 10 +2 Commenting on the index, IDEA …

Alexion Pharmaceuticals

Roche Tops the Pharmaceutical Innovation Index for the First Time; AstraZeneca Ranks 1st for Its Pipeline | PR Newswire | 4/8/2020

Alexion Pharmaceuticals 7 New Merck & Co 8 -3 Shionogi & Co 9 New Johnson & Johnson 10 +1 Regeneron Pharmaceuticals 10 +7 Pharmaceutical Invention Index 2020 Companies 2020 Pharmaceutical Invention Index Change from 2019 AstraZeneca 1 0 Bristol-Myers Squibb 2 +4 Eli Lilly 3 0 Novartis 4 0 Gilead Sciences 5 +6 Regeneron Pharmaceuticals 6 +1 AbbVie 7 -2 Merck & Co 7 +8 Vertex Pharmaceuticals 9 -4 Roche 10 +2 Commenting …

Biogen

Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More - March 18, 2020 - Zacks.com | 3/18/2020

… is actively preparing for a phase II study to evaluate mRNA-1273. Regeneron Up on Identification of Antibodies for Coronavirus : Regeneron Pharmaceuticals ( REGN - Free Report ) announced that it has identified antibodies, which can possibly treat … study in the second half of 2020. Vir Collaborates With Biogen for COVID-19 Treatment : Vir Biotechnology, Inc. ( VIR - Free Report ) announced that it has signed a letter of intent with biotech bigwig, Biogen Inc …

Edwards Lifesciences

The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates | Yahoo News | 3/18/2020

… last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) BioNTech SE – ADR (NASDAQ: BNTX ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) ( Updated on its COVID-19 treatment development plan) Down In … TECHNOLOGIE/S ADR (NASDAQ: DBVT ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Edwards Lifesciences Corp (NYSE: EW ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Enzo Biochem, Inc. (NYSE: ENZ ) Erytech Pharma SA (NASDAQ: ERYP ) Evogene Ltd (NASDAQ: EVGN ) Evolus …

Biohaven

The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates | 3/18/2020

… last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) BioNTech SE – ADR (NASDAQ: BNTX ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) ( Updated on its COVID-19 treatment development plan) Down In … Sciences International, Inc. (NASDAQ: BDSI ) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BIOLASE Inc (NASDAQ: BIOL ) Biomerica, Inc. (NASDAQ: BMRA ) BioTelemetry Inc (NASDAQ: BEAT ) bluebird bio Inc (NASDAQ: BLUE ) BridgeBio …

BDSI

The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates | 3/18/2020

… last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) BioNTech SE – ADR (NASDAQ: BNTX ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) ( Updated on its COVID-19 treatment development plan) Down In … BPTH ) Biocept Inc (NASDAQ: BIOC ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BIOLASE Inc (NASDAQ: BIOL ) Biomerica, Inc. (NASDAQ: BMRA ) BioTelemetry Inc (NASDAQ: BEAT …

Citigroup

Stocks making the biggest moves midday: Las Vegas Sands, Twitter, JPMorgan Chase, Beyond Meat | CNBC | 4/28/2020

… already reflected in the stock price. Twitter is set to report its quarterly earnings on Thursday. JPMorgan Chase , Goldman Sachs , Citigroup , Bank of America , Wells Fargo — Shares of bank stocks rose as interest rates got … alone, on pace for its best month since February 1999. Regeneron Pharmaceuticals — Regeneron shares dropped more than 3% after the company said a U.S. trial using Kevzara to treat coronavirus didn’t have a notable benefit …

Goldman Sachs

Stocks making the biggest moves midday: Las Vegas Sands, Twitter, JPMorgan Chase, Beyond Meat | CNBC | 4/28/2020

… impact is already reflected in the stock price. Twitter is set to report its quarterly earnings on Thursday. JPMorgan Chase , Goldman Sachs , Citigroup , Bank of America , Wells Fargo — Shares of bank stocks rose as interest … alone, on pace for its best month since February 1999. Regeneron Pharmaceuticals — Regeneron shares dropped more than 3% after the company said a U.S. trial using Kevzara to treat coronavirus didn’t have a notable benefit …

Alkermes

The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates | 3/18/2020

… last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) BioNTech SE – ADR (NASDAQ: BNTX ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) ( Updated on its COVID-19 treatment development plan) Down In … Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) AngioDynamics, Inc. (NASDAQ: ANGO ) Anika Therapeutics Inc (NASDAQ: ANIK ) Antares …

SunTrust Bank

Do Hedge Funds Love SunTrust Banks, Inc. (STI)? | Yahoo News | 12/3/2019

… believe it isn’t a waste of time to check out hedge fund sentiment before you invest in a stock like ;SunTrust Banks, Inc. (NYSE: a href=”http://www.insidermonkey.com/insider-trading/company/suntrust+banks+inc/750556 … will examine companies such as O’Reilly Automotive Inc (NASDAQ: ORLY ), Regeneron Pharmaceuticals Inc (NASDAQ: REGN ), and ONEOK, Inc. (NYSE: OKE ) to gather more data points. Our calculations also showed that STI isn’t among the 30 …

Morgan Stanley

🌎 Nutanix Sold, Beyond Meat Sold, Brookline Bancorp Sold and more… | 12/3/2019

… for Netflix Stock My Top Marijuana Pick Is Booming (Ad) Cyber Monday; Who Will Be Crowned King Of The Internet Morgan Stanley Slaps Roku With Downgrade After Massive Rally How Level II Quotes Can Transform … Sell 3,750 shares @ $29.00 $108,750.00 11/27/2019 View $28.60 Read More Regeneron Pharmaceuticals ( NASDAQ:REGN ) Joseph L Goldstein (Director) Sell 1,000 shares @ $370.00 $370,000.00 11/27/2019 View $366.37 Read More Reinsurance Group of America ( NYSE:RGA ) John …

OrbiMed Advisors

Orbimed Advisors LLC Increases Stock Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) - TheOlympiaReport | 11/30/2019

Orbimed Advisors LLC increased its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 5.7% in the 3rd its most recent disclosure with the Securities and Exchange Commission. The firm owned 228,100 shares of the biopharmaceutical company’s stock after purchasing an additional 12,300 shares during the quarter. Orbimed Advisors LLC owned 0.21% of Regeneron Pharmaceuticals worth $63,275,000 as of its most recent filing with the Securities and Exchange Commission. Several other …

Atlas Venture

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… previously Tekmira) ARIZ Precision Medicine Arrowhead Pharmaceuticals Ascletis Pharma Asklepios BioPharmaceutical Institute of Molecular and Cell Biology (IMCB), A STAR Atlas Venture AUM LifeTech Avecia Biotechnology Avidity Biosciences Axovant Gene Therapies Bain Capital Life Sciences … Investment Quark Pharmaceuticals RA Capital Management Radboud University Regen BioPharma Regeneron Pharmaceuticals Regulus Therapeutics Remeditex Ventures ReNeuron RiboBio Rich Yield Capital Santaris Pharma (Acquired by Roche) Roivant Sciences Rolling Boulder Investment Rosetta Genomics Rubicon Genomics …

C-Bridge Capital

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… Boehringer Ingelheim Boston Children’s Hospital Boulder Ventures Brace Pharma Capital Bristol- Myers Squibb Broad Institute Broadview Ventures Calimmune CAMP4 Therapeutics C-Bridge Capital Cell Signaling Technology Cellecta Celsion Cenix BioScience Charoen Pokphand Group Children’s Hospital … Investment Quark Pharmaceuticals RA Capital Management Radboud University Regen BioPharma Regeneron Pharmaceuticals Regulus Therapeutics Remeditex Ventures ReNeuron RiboBio Rich Yield Capital Santaris Pharma (Acquired by Roche) Roivant Sciences Rolling Boulder Investment Rosetta Genomics Rubicon Genomics …

Piper Jaffray

Regeneron Announces Upcoming Investor Conference Presentations | PR Newswire | 11/12/2019

TARRYTOWN, N.Y. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management presentations as follows: Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day, at 11:15 a.m. EST on Monday, November 18, 2019 Piper Jaffray 31 st Annual Healthcare Conference at 8:00 a.m. EST on Tuesday, December 3, 2019 The sessions may be accessed from the “Investors & Media” page of Regeneron’s website at http://investor.regeneron.com/events-and-presentations . Replays of the webcasts will …

Zacks Equity Research

Celgene (CELG) Hits 52-Week High, Can the Run Continue? | Zacks | 11/11/2019

You follow 52 Week High - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Shares of Celgene ( CELG - Free Report ) have been … Health ( GHDX - Free Report ) , Alexion Pharmaceuticals ( ALXN - Free Report ) , and Regeneron Pharmaceuticals ( REGN - Free Report ) , all of which currently have a Zacks Rank of at least 2 and a VGM Score of at least B …

Jefferies Financial Group

Investment Analysts’ Price Target Changes for November, 6th (ABBN, ADS, BMW, BNR, BOSS, CC, DTE, DVA, EVK, FRA) | 11/6/2019

… neutral rating on the stock. Bayerische Motoren Werke (ETR:BMW) was given a €70.00 ($81.40) price target by analysts at Jefferies Financial Group Inc. The firm currently has a neutral rating on the stock. Bayerische … Leerink Swann currently has an outperform rating on the stock. Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by BMO Capital Markets to $358.00. They currently have a market perform rating on the stock …

BlackRock Inc.

BlackRock Inc. Raises Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) - WKRB News | 11/6/2019

BlackRock Inc. lifted its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.0% in the 2nd quarter, according to the company in its most recent 13F filing Commission. The fund owned 6,045,652 shares of the biopharmaceutical company’s stock 2,744 shares during the period. BlackRock Inc. owned 5.50% of Regeneron Pharmaceuticals worth $1,892,289,000 at the end of the most recent quarter. Other hedge funds also recently modified their holdings …

SVB Leerink

Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/5/2019

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Q3 2019 Earnings Conference Call November 5, 2019 8:30 AM ET Company Participants Justin Holko - VP, IR Len Schleifer - Co-Founder, President & CEO George Yancopoulos - Founding Scientist, President, Chief Scientific … Co. Geoffrey Meacham - Bank of America Merrill Lynch Geoffrey Porges - SVB Leerink Terence Flynn - Goldman Sachs Group Matthew Harrison - Morgan Stanley Yaron Werber - Cowen and Company Evan Seigerman - Crédit Suisse Yatin Suneja - Guggenheim Securities Matthew …

Merrill Lynch

Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/5/2019

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Q3 2019 Earnings Conference Call November 5, 2019 8:30 AM ET Company Participants Justin Holko - VP, IR Len Schleifer - Co-Founder, President & CEO George Yancopoulos - Founding Scientist, President, Chief Scientific Officer & Director Marion McCourt - SVP & Head, Commercial Robert Landry - EVP, Finance & CFO Conference Call Participants Christopher Raymond - Piper Jaffray Companies Aaron Gal - Sanford C. Bernstein & Co. Geoffrey Meacham - Bank of America Merrill Lynch Geoffrey Porges …

Daiichi Sankyo

AstraZeneca Tops the First Pharmaceutical Invention Index | PR Newswire | 11/3/2019

Regeneron Pharmaceuticals 7 Daiichi Sankyo 8 GSK 9 Biogen 10 Commenting on the index, IDEA Pharma’s CEO, Mike Rea said: “There’s a critical distinction between invention and innovation – success is achieved by discovering and developing meaningfully great medicines (invention) and getting those medicines to market, and to patients (innovation). It is wonderful to see a company of AstraZeneca’s scale and history able to turn around its fortunes in a relatively …

Sterling Capital Management

Sterling Capital Management LLC Sells 15,901 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 9/22/2019

Sterling Capital Management LLC decreased its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 92.4% in the second quarter, HoldingsChannel reports. The institutional investor owned 1,316 shares of the biopharmaceutical company’s stock after selling 15,901 shares during the period. Sterling Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $412,000 at the end of the most recent quarter. A number of other institutional investors and hedge funds also …

BB&T

BB&T Securities LLC Raises Stock Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) | 8/31/2019

Posted by ABMN Staff on Aug 31st, 2019 // No Comments BB&T Securities LLC boosted its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 15.5% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 14,297 shares of the biopharmaceutical company’s stock after buying an additional 1,914 shares during the period. BB&T Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $4,474,000 as …

Menlo Ventures

Benchling Nabs $34.5M to Power Life Sciences R&D Cloud Platform | HIT Consultant | 7/25/2019

… CA-based life sciences R&D cloud platform announced it has raised $34.5 million in Series C funding led by Menlo Ventures with new investors Lead Edge Capital and Y Combinator Continuity as well as … science industry leaders such as Zoetis, Beam Therapeutics, Zymergen and Regeneron Pharmaceuticals. Scientists working in cutting-edge fields like CRISPR, CAR-T immunotherapy and genetic engineering depend on Benchling’s suite of cloud applications to design …

Barings LLC

Barings LLC Grows Stake in Regeneron Pharmaceuticals Inc (REGN) - American Banking News | 5/26/2019

Barings LLC lifted its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 137.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,107 shares of the biopharmaceutical company’s stock after purchasing an additional 2,380 shares during the period. Barings LLC’s holdings in Regeneron Pharmaceuticals were worth $1,686,000 as of its most recent filing …

Leerink Partners

Assessing If Regeneron Is In Value Territory After Shares Tumble - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) | Seeking Alpha | 5/9/2019

… analysts set a price target in the range of $353-480: Analyst Firm Price Target Rating Success Rate Canaccord Genuity $353 Hold 44% UBS $440 Buy 42% Oppenheimer $480 Buy 41% Guggenheim - Hold 47% Leerink Partners - Buy 46% RBC Capital - Hold 57% Source: Tipranks The latest quarterly earnings miss is a setback, but the results are not enough reason to change my positive outlook. Source: finbox.io If I assume a downside …

Cantor Fitzgerald

Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/7/2019

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Q1 2019 Results Earnings Conference Call May 7, 2019 8:30 AM ET Company Participants Mark Hudson - Senior Manager, Investor Relations Leonard Schleifer - Founder, President & Chief Executive Officer George Yancopoulos - Founding … of America Matthew Luchini - BMO Brian Skorney - Baird Alethia Young - Cantor Fitzgerald Operator Good morning and welcome to the Regeneron Pharmaceuticals First Quarter 2019 Earnings Conference Call. My name is Brandon and I will be …

Third Rock Ventures

Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus | PR Newswire | 11/29/2017

… Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus 00 TARRYTOWN, N.Y. and BOSTON Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Decibel Therapeutics, Inc., today announced a collaboration to discover … in biotech,” said Kevin Starr , Co-Founder and Partner at Third Rock Ventures and Chairman of Decibel. “The scope of the collaboration in research and discovery, as well as the retention by the younger biotechnology …

Mayo Clinic

VA to participate in clinical trials for blood plasma therapy, remdesivir and sarilumab | NBC News | 5/2/2020

… and sarilumab The VA said Friday that it will take part in clinical trials for COVID-19 treatments, including a Mayo Clinic study on whether the antibodies in blood plasma from recovered patients can help … against COVID-19. In Atlanta, the VA is working with Regeneron Pharmaceuticals to assess whether sarilumab, a drug normally taken to treat rheumatoid arthritis, may be an effective treatment. Veteran patients interested in participating can …

Beth Israel Deaconess Medical Center

Coronavirus patients at four Mass. hospitals enrolled in trial of Sanofi drug | Boston Globe | 4/10/2020

Regeneron Pharmaceuticals of New York. Advertisement Massachusetts General Hospital, Brigham and Women’s Hospital, Tufts Medical Center, and Beth Israel Deaconess Medical Center are among 64 hospitals at 51 US sites where the drug is being tested. All told, about 1,000 patients are participating in the study. Sibold couldn’t specify how many of them are in Massachusetts. Patients began receiving doses the week of March 16. Sibold said it’s way too …

Northwell Health

Covid-19 clinical trials expedited as trials in other diseases put on hold, Northwell exec says - MedCity News | 3/22/2020

Northwell Health – a healthcare system that operates hospitals and clinics in New York and adjacent suburbs upstate and on Long Island – announced they had started enrolling patients in the trials for Gilead Sciences’ Phase III trial program of remdesivir as well as Regeneron Pharmaceuticals and Sanofi’s Phase II/III trial of Kevzara (sarilumab) for treating patients with SARS-CoV-2. While Northwell is one of many sites, its officials emphasized …

UT Southwestern Medical Center

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool | PR Newswire | 11/28/2019

Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool News provided by Research and Markets Nov 28, 2019, 07:00 ET DUBLIN , Nov. 28, 2019 /PRNewswire/ – The “Genome Editing Services Market-Focus on CRISPR 2019-2030” report has been added to ResearchAndMarkets.com’s offering. This report features an extensive study of the current landscape of CRISPR-based genome editing service providers. The study presents an …

University of Texas MD Anderson Cancer Center

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… University Karolinska Institutet Department of Inhalation Research, Korea Institute of Toxicology Legend Sky Investment Lincoln Park Capital Fund Lonza The University of Texas MD Anderson Cancer Center Mallinckrodt Pharmaceuticals Marina Biotech Massachusetts Institute of Technology … Investment Quark Pharmaceuticals RA Capital Management Radboud University Regen BioPharma Regeneron Pharmaceuticals Regulus Therapeutics Remeditex Ventures ReNeuron RiboBio Rich Yield Capital Santaris Pharma (Acquired by Roche) Roivant Sciences Rolling Boulder Investment Rosetta Genomics Rubicon Genomics …

The University of Texas MD Anderson Cancer Center

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… Hopkins University Karolinska Institutet Department of Inhalation Research, Korea Institute of Toxicology Legend Sky Investment Lincoln Park Capital Fund Lonza The University of Texas MD Anderson Cancer Center Mallinckrodt Pharmaceuticals Marina Biotech Massachusetts Institute of … Investment Quark Pharmaceuticals RA Capital Management Radboud University Regen BioPharma Regeneron Pharmaceuticals Regulus Therapeutics Remeditex Ventures ReNeuron RiboBio Rich Yield Capital Santaris Pharma (Acquired by Roche) Roivant Sciences Rolling Boulder Investment Rosetta Genomics Rubicon Genomics …

Harvard Medical School

Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting | 11/23/2019

… with rGBM which is typically rapidly fatal,” said Dr. Antonio Chiocca, M.D., Ph.D., poster author and Professor of Neurosurgery at Harvard Medical School, Surgical Director of the Center for Neuro-Oncology at Dana-Farber Cancer … 2 trial to evaluate Controlled IL-12 in combination with Regeneron Pharmaceuticals’ PD-1 antibody Libtayo ® (cemiplimab-rwlc) in June 2019. Learn more about Controlled IL-12 online at https://ziopharm.com/controlled-il-12/ . The …

University of Texas Southwestern Medical Center

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award | PR Newswire | 11/22/2019

TARRYTOWN, N.Y. Columbia’s highest honor bestowed for Yancopoulos’ contributions to science and medicine Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that George D. Yancopoulos , M.D., Ph.D., Co-Founder, President and Chief Scientific Officer, was awarded … Regental Professor of Molecular Genetics and Internal Medicine at the University of Texas Southwestern Medical Center . Biography & Career Accomplishments Yancopoulos, the son of Greek immigrants and a life-long New Yorker, attended New York City …

Cleveland Clinic

Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 Nasdaq:KNSA | Globe Newswire | 11/16/2019

… recurrent pericarditis, for which we expect top-line data in the second half of 2020.” Dr. Allan Klein, MD, of Cleveland Clinic and co-principal investigator for the trial, presented Efficacy and Safety of Rilonacept … 1β (IL-1β) signaling. Rilonacept was discovered and developed by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the FDA under the brand name ARCALYST ® for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), which …

UC Davis Medical Center

Ophthalmology Times® Announces Winners of 3rd Annual Research Scholar Honoree Program | Business Wire | 10/30/2019

… Retinal Diseases and Associated Risk Factors in an African Population from Mwanza, Tanzania.” Fifth place – Michael P. Ellis, M.D. resident, UC Davis Medical Center, Sacramento, California, “Cost Analysis of Tele-ophthalmology Screening for Diabetic Retinopathy … This program is supported through an unrestricted educational grant from Regeneron Pharmaceuticals. To view the complete list of honorees and faculty judges, click here . About Ophthalmology Times ® Ophthalmology Times ® is a multimedia platform that offers …

Henry Ford Hospital

Ophthalmology Times® Announces Winners of 3rd Annual Research Scholar Honoree Program | Business Wire | 10/30/2019

… faculty judges present at the meeting. The top five honorees are as follows: First place – Shravani Mikkilineni, M.D., MBA, resident, Henry Ford Hospital, Detroit, Michigan, “T2 Magnetic Resonance Assay for Detection of Ocular Candidiasis.” Second … This program is supported through an unrestricted educational grant from Regeneron Pharmaceuticals. To view the complete list of honorees and faculty judges, click here . About Ophthalmology Times ® Ophthalmology Times ® is a multimedia platform that offers …

Memorial Sloan Kettering

Novel Cell Sorting and Separation Markets, 2030 | PR Newswire | 10/7/2019

… Lupin Mackay Memorial Hospital Massachusetts Institute of Technology Mayo Clinic Foundation MD Anderson Cancer Center MDxK Medigen Biotech MeMed Diagnostics Memorial Sloan Kettering Cancer Center Menarini Silicon Biosystems Merck Metabiota Microbix Biosystems MicroMedicine Middle East … Quad Technologies Qventures R&D Systems RareCyte Real Tech Fund Regeneron Pharmaceuticals Regionalt Cancercentrum Stockholm-Gotland RIKEN Bioresource Research Center Riverside’s Highlander Venture Fund Roche Roswell Park Comprehensive Cancer Center Rowan University Rush University Medical …

MD Anderson Cancer Center

Novel Cell Sorting and Separation Markets, 2030 | PR Newswire | 10/7/2019

… Livzon Pharmaceuticals London Business Angels LPATH LumaCyte Luminex LungLifeAI Lupin Mackay Memorial Hospital Massachusetts Institute of Technology Mayo Clinic Foundation MD Anderson Cancer Center MDxK Medigen Biotech MeMed Diagnostics Memorial Sloan Kettering Cancer Center Menarini … Quad Technologies Qventures R&D Systems RareCyte Real Tech Fund Regeneron Pharmaceuticals Regionalt Cancercentrum Stockholm-Gotland RIKEN Bioresource Research Center Riverside’s Highlander Venture Fund Roche Roswell Park Comprehensive Cancer Center Rowan University Rush University Medical …

HCA

Fibrogen names James A. Schoeneck interim CEO | MarketWatch | 8/26/2019

HCA Healthcare Inc, Regeneron Pharmaceuticals Inc, Sells Horizon Therapeutics PLC, Array BioPharma Inc, Allergan PLC Jul. 22, 2019 at 7:38 p.m. ET on GuruFocus.com Late-stage study underway for FibroGen’s pamrevlumab in IPF Jul. 22, 2019 at 8:42 Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.8 million of Shares Jul. 12, 2019 at 5:15 p.m. ET on GuruFocus.com FibroGen (FGEN) Investor Presentation - Slideshow Jun. 12, 2019 at 3:14 Fibrogen …

HCA Healthcare

Fibrogen names James A. Schoeneck interim CEO | MarketWatch | 8/26/2019

HCA Healthcare Inc, Regeneron Pharmaceuticals Inc, Sells Horizon Therapeutics PLC, Array BioPharma Inc, Allergan PLC Jul. 22, 2019 at 7:38 p.m. ET on GuruFocus.com Late-stage study underway for FibroGen’s pamrevlumab in IPF Jul. 22, 2019 at 8:42 Fibrogen Inc (FGEN) CEO Thomas B Neff Sold $1.8 million of Shares Jul. 12, 2019 at 5:15 p.m. ET on GuruFocus.com FibroGen (FGEN) Investor Presentation - Slideshow Jun. 12, 2019 at 3:14 Fibrogen …

Lenox Hill Hospital, New York NY

FDA OKs 1st Drug for Sinusitis With Nasal Polyps | WebMD | 6/28/2019

… addition to steroids, antibiotics and surgery.” Dr. Jordan Josephson is an ear, nose and throat (ENT) and sinus specialist at Lenox Hill Hospital, also in New York City. He said that early studies suggest Dupixent … Josephson said. Continued According to the FDA, Dupixent, made by Regeneron Pharmaceuticals, was originally approved in 2017 for certain patients 12 and older with eczema. In 2018, Dupixent was also approved as an add-on …

Staten Island University Hospital

FDA OKs 1st Drug for Sinusitis With Nasal Polyps | WebMD | 6/28/2019

… and allergists have been waiting years for this approval,” said Dr. David Hiltzik, who directs head and neck surgery at Staten Island University Hospital in New York City. “It adds a novel approach that has … Josephson said. Continued According to the FDA, Dupixent, made by Regeneron Pharmaceuticals, was originally approved in 2017 for certain patients 12 and older with eczema. In 2018, Dupixent was also approved as an add-on …

Tenet Healthcare

Healthcare stocks under pressure ahead of Dem debate - AmerisourceBergen Corporation (NYSE:ABC) | Seeking Alpha | 6/26/2019

Regeneron Pharmaceuticals ( REGN -1.9% ), Incyte ( INCY -1.5% ), Sage Therapeutics ( SAGE -1.2% ), UnitedHealth Group ( UNH -1.1% ), Cardinal Health ( CAH -0.2% ), McKesson ( MCK -1.2% ), AmerisourceBergen ( ABC -0.6% ), Tenet Healthcare ( THC -1.8% ), HCA ( HCA -1.5% ), Humana ( HUM -0.2% ) See all stocks on the move » Now read: Bristol-Myers Squibb: Share Repurchases No Benefit To Shareholders …

Aetna

T.E.N. Announces 2019 ISE® North America Award Winners | 11/14/2019

The University of Chicago Medicine, Cox Communications, Woodforest National Bank, Regeneron Pharmaceuticals, Emory University, Comcast Corporation and Mastercard take home awards. Press Release - updated: Nov 14, 2019 10:00 EST ATLANTA, November 14, 2019 (Newswire.com) - T.E.N … included executives and project teams from leading organizations such as Aetna, AIG, AT&T, Bank of America, Comcast, Cox Automotive, HMS, Jabil, NCR, PayPal, SunTrust and VISA. Source: T.E.N …

Justice Democrats Accuses Buttigieg of Abandoning Medicare for All After Taking ‘Tons of Cash’ From Corporate Interests | 11/13/2019

… Aetna, Regeneron Pharmaceuticals, Pfizer and Indiana’s Eli Lilly & Co. 9/19/2019 . Buttigieg shifts tactics and goes on the attack : “Anyone who lets the words Medicare for All escape their lips should tell us just as plainly how they plan to get there.” 9/19/2019. Buttigieg goes after Warren : “Warren is known for being straightforward and was extremely evasive when asked that question, and we’ve seen that repeatedly.” 10/15/2019 . Buttigieg attacks Warren at …

Humana

🌎 The Week Ahead for 11/3/2019 | 11/3/2019

… Technology Inc. ( MCHP ), Newmont Goldcorp Corp ( NEM ), PetroChina Company Limited ( PTR ), Plains All American Pipeline, L.P. ( PAA ), PPL Corp ( PPL ), Regeneron Pharmaceuticals Inc ( REGN ), SK Telecom Co Ltd ( SKM ), Telefonica Brasil SA ( VIV ), Telefonica S.A … FOX ), Fox Corp ( FOXA ), Godaddy Inc ( GDDY ), Hologic, Inc. ( HOLX ), Humana Inc ( HUM ), IAC/InterActiveCorp ( IAC ), IQIYI Inc ( IQ ), Liberty Global PLC ( LBTYA ), Liberty Global PLC ( LBTYB ), Liberty Global PLC ( LBTYK ), Manulife Financial Co. ( MFC …

Hedge Funds Are Selling Canadian Imperial Bank of Commerce (CM) | Yahoo News | 10/11/2019

Humana Inc (NYSE: HUM ), eBay Inc (NASDAQ: EBAY ), and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ). This group of stocks’ market caps resemble CM’s market cap. [table] Ticker, No of HFs with positions, Total Value of HF Positions (x1000), Change in HF Position MNST,38,2929071,5 HUM,62,4261860,20 EBAY,47,3898481,-1 REGN,37,1330987,6 Average,46,3105100,7.5 [/table] View table here if you experience formatting issues. As you can see these stocks had an average …

Wellcare

Dominion Resources, Inc. (NYSE:D), WellCare Health Plans, Inc. (NYSE:WCG) - 11 Stocks With The Highest Gross Margins | Benzinga | 10/28/2019

… WellCare Health Plans, Inc. (NYSE: WCG ), 98.5% margin. Sempra Energy (NYSE: SRE ), 98.1% margin. Celgene Corporation (NASDAQ: CELG ), 96.2% margin. Incyte Corporation (NASDAQ: INCY ), 95.9% margin. MarketAxess Holdings Inc. (NASDAQ: MKTX ), 94.7% margin. Realty Income Corp (NYSE: O ), 94.5% margin. Tripadvisor Inc (NASDAQ: TRIP ), 94.4% margin. Regeneron Pharmaceuticals Inc (NASDAQ: REGN ), 93.4% margin. Alliant Energy Corporation (NASDAQ: LNT ), 93.4% margin. Northern Trust Corporation (NASDAQ: NTRS ), 92.8% margin. Benzinga’s Take Investors …

Health care is one of the stock market’s healthiest sectors right now - MarketWatch | 7/8/2019

… share - year-earlier quarter Estimated increase in sales per share Cigna Corp. CI, -1.05% $35,039 $11,477 205% $92.34 $46.78 97% WellCare Health Plans Inc. WCG, -0.47% $6,625 $4,639 43% $131.67 $102.45 29% CVS Health Corp … ResMed Inc. RMD, -0.42% $700 $624 12% $4.88 $4.33 13% Regeneron Pharmaceuticals Inc. REGN, -1.36% $1,803 $1,608 12% $16.45 $14.05 17% Alexion Pharmaceuticals Inc. ALXN, -3.84% $1,172 $1,047 12% $5.23 $4.70 11% Humana Inc. HUM …

Cigna

Highest-paid CEOs in 2018: Who made the list from healthcare | Becker’s Hospital Review | 5/28/2019

Regeneron Pharmaceuticals, Leonard Schleifer — $27 million Centene, Michael Neidorff — $26 million Universal Health Services, Alan Miller — $24 million Abbott Laboratories, Miles White — $23 million CVS Health, Larry Merlo — $22 million Merck, Kenneth Frazier — $21 million Abbvie, Richard Gonzalez — $21 million Johnson & Johnson, Alex Gorsky — $20 million HCA Healthcare, R. Milton Johnson — $20 million Pfizer, Ian Read — $20 million Bristol-Myers Squibb, Giovanni Caforio — $19 million Cigna, David Cordani — $19 million …

I recently had a look at SPDR sectors through the last two m | Seeking Alpha | 10/12/2017

Cigna 10 .44 .02 Stryker 6 36.41 1.20 Beckton Dickinson 45 81.55 1.49 Boston Scientific 0 0 0 Intuitive Surgical 0 0 0 Express Scripts 0 0 0 Vertex Pharmaceuticals 0 0 0 Humana 6 11.4 .66 Regeneron Pharmaceuticals 0 0 0 McKesson Corp 10 with hold 4.96 .89 Baxter 0 div cut 32.19 1.02 Alexion Pharmaceuticals 0 0 0 Zoetis 3 23 .66 Illumina 0 0 0 Bard CR …

George D. Yancopoulos

Sanofi: Premature termination of the phase III trial of Libtayo® (cemiplimab) monotherapy in the first line treatment of advanced non-small cell lung cancer due to a highly significant improvement in | Yahoo News | 4/28/2020

… to chemotherapy Sanofi and Regeneron plan regulatory submissions in 2020 Paris and Tarrytown (New York) – April 27, 2020 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announce that the Phase III trial comparing the PD … monotherapy by the FDA changed the therapeutic paradigm “, said Dr. George D. Yancopoulos, Ph.D., co-founder, President and Scientific Director of Regeneron. ” We are very satisfied with the results of this trial which demonstrated an …

John Reed

Sanofi: Premature termination of the phase III trial of Libtayo® (cemiplimab) monotherapy in the first line treatment of advanced non-small cell lung cancer due to a highly significant improvement in | Yahoo News | 4/28/2020

… to chemotherapy Sanofi and Regeneron plan regulatory submissions in 2020 Paris and Tarrytown (New York) – April 27, 2020 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announce that the Phase III trial comparing the PD … new therapeutic option to this category of patients ”, said Doctor John Reed, Ph.D., World Research and Development Manager at Sanofi. “We are grateful to the investigators and patients who participated in this international trial. “ Lung …

Geoffrey Porges

Drugmakers’ financial fortunes during Covid-19 may hinge on their product mix | MedCity News | 4/23/2020

… positioned to weather the plague mostly unscathed and others more likely to suffer what one of the analysts, SVB Leerink’s Geoffrey Porges, called “demand erosion.” An interviewed expert, Brett Larson, principal at health consultancy firm … Gilead Sciences ; those with the most discretionary products were Amgen , Regeneron Pharmaceuticals and GlaxoSmithKline . Still, everything may not neatly fall along these lines of necessary and discretionary. For instance, Eduardo Schur, global practice leader for …

Donald Trump

Trump Plans Steady Economic Reboot: 5 Coronavirus-Proof Bets | Yahoo News | 4/17/2020

U.S. President Donald Trump released “Opening Up America Again” guidelines on Apr 16. The latest protocols suggest a phased opening of the U.S. economy that has been battered by coronavirus-induced lockdowns and restrictions on … year ago. Long-term earnings growth rate stands at 26.6%. Regeneron Pharmaceuticals REGN will most likely introduce a coronavirus treatment. The company identified hundreds of virus-neutralizing, fully human antibodies from which it will select …

Anthony Fauci

Lilly arthritis pill to be included in NIAID’s Phase III Covid-19 trial of multiple drugs - MedCity News | 4/13/2020

L-R: NIAID Vaccine Research Center Director John Mascola, NIAID Director Anthony Fauci and President Donald Trump, at a March 3 briefing about research on Covid-19 A large drug company is enlisting one of … and Novartis’ Jakafi (ruxolitinib) and Pfizer’s Xeljanz (tofacitinib), along with Regeneron Pharmaceuticals and Sanofi’s Kevzara (sarilumab) and Roche’s Actemra (tocilizumab). “There is an urgent need for new strategies to help hospitalized Covid-19 patients, many …

George Yancopoulos

Research On Monoclonal Antibody Treatments Takes Aim At COVID-19 : Shots - Health News : NPR | 3/26/2020

… Against The Coronavirus Facebook Twitter Flipboard Email March 26, 2020 4:57 PM ET Joe Palca Twitter Facebook Enlarge this image Regeneron Pharmaceuticals, headquartered near Tarrytown, N.Y., is just one of the companies now working to … uses special mice that essentially have a human immune system. George Yancopoulos, Regeneron’s chief scientific officer, says they already have hundreds of antibody candidates. “And then, ultimately, we will choose the top two,” Yancopoulos says …

Kelly Gooch

Coronavirus, March 20: 14 notes directly from physicians, hospitals | 3/20/2020

Kelly Gooch at with any announcements from your system related to COVID-19. New York 1. The Feinstein Institutes for Medical Research, the research arm of New Hyde Park-based Northwell Health , announced the enrollment of three large-scale COVID-19 clinical trials. Northwell said Feinstein and Gilead Sciences and Regeneron Pharmaceuticals will join forces to identify effective treatments for COVID-19 patients who are in the hospital in moderate …

Mackenzie Garrity

Coronavirus, March 20: 14 notes directly from physicians, hospitals | 3/20/2020

Mackenzie Garrity at or Kelly Gooch at with any announcements from your system related to COVID-19. New York 1. The Feinstein Institutes for Medical Research, the research arm of New Hyde Park-based Northwell Health , announced the enrollment of three large-scale COVID-19 clinical trials. Northwell said Feinstein and Gilead Sciences and Regeneron Pharmaceuticals will join forces to identify effective treatments for COVID-19 patients who are in …

Virginia Mason

Coronavirus, March 20: 14 notes directly from physicians, hospitals | 3/20/2020

… Northwell Health , announced the enrollment of three large-scale COVID-19 clinical trials. Northwell said Feinstein and Gilead Sciences and Regeneron Pharmaceuticals will join forces to identify effective treatments for COVID-19 patients who are … struggles due to the coronavirus pandemic. Washington 3. Seattle-based Virginia Mason Medical Center developed an online assessment for patients questioning whether they have contracted COVID-19. The COVID-19 patient assessment tool currently does …

Jim Cramer

Regeneron begins clinical trials to treat severe COVID-19 symptoms | CNBC | 3/18/2020

VIDEO 2:33 02:33 Jim Cramer: More negative virus news needed before indexes can bottom Mad Money with Jim Cramer Regeneron Pharmaceuticals this week initiated test trials of an arthritis drug as a potential remedy for the worst symptoms of COVID-19, the disease caused by the novel coronavirus. The biotech giant announced Monday it launched a clinical program using Kevzara, a commercial medicine that treats active rheumatoid arthritis, and recruiting …

Melinda Gates

Global Pandemic Reiterates the Need for Infectious Disease Therapeutics | PR Newswire | 3/16/2020

… serious illness occurs in 16% of cases. NanoViricides, Inc. (NYSE: NNVC ), Johnson & Johnson (NYSE: JNJ ), Quest Diagnostics, Inc. (NYSE: DGX ), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ), INOVIO Pharmaceuticals, Inc. (NASDAQ: INO ) COVID-19 is an infectious … has received a new $5 million grant from the Bill & Melinda Gates Foundation to accelerate the testing and scale up of CELLECTRA® 3PSP proprietary smart device for the intradermal delivery of INO-4800, a DNA …

Anna Stashower

PM360 Announces Winners Of 2019 Pharma Choice Awards | PR Newswire | 1/24/2020

… year’s best creative then giving the thousands of people who do that work a chance to cast their vote,” said Anna Stashower , CEO/Publisher, PM360 . “We congratulate all of this year’s winners and are happy … campaign in the Professional Campaign category, and MicroMass Communications, Inc., Regeneron Pharmaceuticals, and Sanofi Genzyme for their “Stay on Track” video in the Video category. This year’s PM360 Pharma Choice winners are: ANIMAL HEALTH GOLD …

Sara Peerun

Visiongain Report Claims There is Huge Potential Within the $39bn Dermatological Drugs Market | PR Newswire | 11/29/2019

… new report today you stay better informed and ready to act. To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/dermatological-drugs … Pfizer PharmaPraxis Photocure Pierre Fabre Provectus Biopharmaceuticals QLT Inc Ranbaxy Regeneron Pharmaceuticals Roche Samsung Bioepis Samsung BioLogics Sandoz Sanofi Schering-Plough Shanghai CP Buojian Pharmaceutical Sidmak Labs Sol-Gel Technologies Ltd Sun Pharma Sunovion Takeda …

Laura Wood

Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA | PR Newswire | 11/27/2019

… Pharmaceuticals) Phyzat Biopharmaceuticals QIAGEN QianHai Fund of Funds Qianhai Shenghui Investment Quark Pharmaceuticals RA Capital Management Radboud University Regen BioPharma Regeneron Pharmaceuticals Regulus Therapeutics Remeditex Ventures ReNeuron RiboBio Rich Yield Capital Santaris Pharma (Acquired by … focused, comprehensive and tailored research. Media Contact: Research and Markets Laura Wood , Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 …

Vas Narasimhan

Novartis to pay US$9.7 bil in latest bet on novel technology | 11/25/2019

Vas Narasimhan was willing to foot the bill, which includes stock options and convertible debt, for a medicine that appears to be moving quickly to the U.S. market where it will compete against existing products from Amgen Inc, Regeneron Pharmaceuticals Inc and Sanofi. Drugmakers are targeting conditions and technologies that can set them apart from rivals, leaving more room for sales growth and allowing them to charge higher prices in …

Len Schleifer

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award | PR Newswire | 11/22/2019

TARRYTOWN, N.Y. Columbia’s highest honor bestowed for Yancopoulos’ contributions to science and medicine Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that George D. Yancopoulos , M.D., Ph.D., Co-Founder, President and Chief Scientific Officer, was awarded … combined with his remarkably synergistic and long-term partnership with Len Schleifer , are the major drivers behind Regeneron’s extraordinary growth and contributions to human health over the years,” said Nobel Prize winner and Regeneron board …

Israel Lowy

Regeneron’s Yancopoulos Receives Columbia College’s Alexander Hamilton Award | PR Newswire | 11/22/2019

TARRYTOWN, N.Y. Columbia’s highest honor bestowed for Yancopoulos’ contributions to science and medicine Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that George D. Yancopoulos , M.D., Ph.D., Co-Founder, President and Chief Scientific Officer, was awarded … Development), who lead the Company’s regulatory and Global Development efforts; Israel Lowy , M.D., Ph.D. (Senior Vice President and Head of Translational Science and Oncology), who leads Regeneron’s clinical program in oncology; and Jay Markowitz , M.D …

J. Joseph Kim

Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results | PR Newswire | 11/12/2019

… and INO-9012, an immune activator encoding IL-12, in combination with Libtayo ® , a PD-1 blocking antibody produced by Regeneron Pharmaceuticals in collaboration with Sanofi. Key interim data from the 52-patient clinical trial … 3107 to treat RRP and INO-5401 for GBM. Dr. J. Joseph Kim , Inovio’s President & CEO, said, “Our recently presented INO-5401 data demonstrated promising efficacy results, in terms of progression-free survival rates, against …

Elizabeth Warren

U.S. company directors compensated more than ever, but now risk backlash | Yahoo News | 11/8/2019

… headhunters Spencer Stuart. But thanks largely to stock grants some earned a lot more than that. Directors at biotechnology company Regeneron Pharmaceuticals Inc received, on average, $1.2 million in compensation last year. That figure does … contender for the Democratic presidential nomination for the 2020 election, Elizabeth Warren, has the boardroom in her sights as she seeks to tackle inequality in American society. As well as proposals such as a wealth …

Marion McCourt

Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/6/2019

… source: The Motley Fool. Nov 05, 2019 , 8:30 a.m. ET Contents: Prepared Remarks: Operator Good morning, and welcome to the Regeneron Pharmaceuticals third-quarter 2019 earnings conference call. My name is Sheryl, and I will … Dr. George Yancopoulos, founding scientist, president and chief scientific officer; Marion McCourt, senior vice president and head of commercial; and Bob Landry, executive vice president and chief financial officer. After our prepared remarks, we will …

Cory Kasimov

Regeneron Pharmaceuticals (REGN) Q3 2019 Earnings Call Transcript | The Motley Fool | 11/6/2019

… source: The Motley Fool. Nov 05, 2019 , 8:30 a.m. ET Contents: Prepared Remarks: Operator Good morning, and welcome to the Regeneron Pharmaceuticals third-quarter 2019 earnings conference call. My name is Sheryl, and I will … want to be there. Operator Our next question comes from Cory Kasimov from JP Morgan. Your line is now open. Matthew Holt – J.P. Morgan – Analyst Hey, guys. Thanks for taking my question. This is Matthew …

David Reardon

Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab) | PR Newswire | 11/5/2019

… INO-9012, an immune activator encoding IL-12, in combination with Libtayo ® (cemiplimab), a PD-1 blocking antibody developed by Regeneron Pharmaceuticals (NASDAQ: REGN ) in collaboration with Sanofi. The data will be featured in a … 12- and 18-month overall survival data next year. Dr. David Reardon , M.D., Coordinating Principal Investigator of the study and the Clinical Director for Neuro-Oncology at the Dana-Farber Cancer Institute, said, “This innovative …

Christopher Raymond

Regeneron Pharmaceuticals, Inc. (REGN) CEO Len Schleifer on Q3 2019 Results - Earnings Call Transcript | Seeking Alpha | 11/5/2019

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Q3 2019 Earnings Conference Call November 5, 2019 8:30 AM ET Company Participants Justin Holko - VP, IR Len Schleifer - Co-Founder, President & CEO George Yancopoulos - Founding Scientist, President, Chief Scientific Officer & Director Marion McCourt - SVP & Head, Commercial Robert Landry - EVP, Finance & CFO Conference Call Participants Christopher Raymond - Piper Jaffray Companies Aaron Gal - Sanford C. Bernstein & Co. Geoffrey Meacham - Bank of America Merrill Lynch Geoffrey Porges …

Bascom Palmer

Ophthalmology Times® Announces Winners of 3rd Annual Research Scholar Honoree Program | Business Wire | 10/30/2019

… Barrier Disruption Maculopathy: A Common, Visually Significant Side-effect in a Growing Population.” Third place – Diana M. Laura, M.D., resident, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, “Genotypic and … This program is supported through an unrestricted educational grant from Regeneron Pharmaceuticals. To view the complete list of honorees and faculty judges, click here . About Ophthalmology Times ® Ophthalmology Times ® is a multimedia platform that offers …

Albert Bourla

Pfizer Edges Higher After Positive Trials for Moderate-to-Severe Eczema Drug | TheStreet | 9/27/2019

Regeneron Pharmaceuticals ( REGN ) won FDA approval for their shared atopic dermatitis treatment, Dupixent, in March 2017. The drug tallied second quarter sales of $557 million, the companies reported, a 166% increase from the same period last year. Separately, Pfizer said Friday that executive board chairman Ian Read would leave his post at the end of the year, with CEO Albert Bourla replacing him on January 1. “It’s been my greatest …